Breast Cancer | Specialty

Phase 3 ASCENT Regimen Accelerated Approval

July 14th 2020

SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews

July 14th 2020

ASCO New Data: PARP Inhibitors

July 14th 2020

KEYNOTE-355 Regimen’s Role in Treatment Paradigm

July 14th 2020

PD-L1 Testing Standard of Practice

July 14th 2020

Phase 3 KEYNOTE-355 Overview

July 14th 2020

Perspectives on Recent Progress: Program Overview

July 14th 2020

Trastuzumab Deruxtecan Shows Broad Benefit in Metastatic HER2+ Breast Cancer

July 13th 2020

William J. Gradishar, MD, discusses the activity of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and the importance of building experience with the drug before evaluating it in combination or moving it into earlier lines of therapy.

Krop Highlights Durable Activity With ADC in HER2+ Breast Cancer

July 12th 2020

Ian E. Krop, MD, PhD, discusses the pivotal data from the DESTINY-Breast01 trial, the need for longer-term follow-up with trastuzumab deruxtecan, and the proper management of interstitial lung disease.

ASCO 2020 Heralds a Handful of Influential Data Across Breast Cancer Settings

July 10th 2020

The 2020 ASCO Virtual Scientific Program delivered a number of important updates to the field of breast cancer, explained Joyce A. O'Shaughnessy, MD.

F-627 Shows Strong, Durable Benefit in Chemotherapy-Induced Neutropenia in Breast Cancer

July 9th 2020

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.

Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer

July 9th 2020

In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.

Yale Cancer Center Study Shows Breast Cancer Detected Earlier in States with Expanded Medicaid Coverage

July 9th 2020

In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act a higher percentage of women with breast cancer had their disease diagnosed at an early stage.

Dr. Litton on the EMBRACA Trial in Advanced BRCA1/2+ Breast Cancer

July 8th 2020

Jennifer K. Litton, MD, discusses the phase 3 EMBRACA trial in patients with germline BRCA1/2-mutated metastatic HER2-negative breast cancer. 

Systemic Therapies Improve Breast Cancer With Brain Metastases Management

July 7th 2020

Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival for these patients, and a number of agents on the horizon.

Expert Expands on Emerging Developments in Metastatic TNBC

July 7th 2020

Hatem Soliman, MD, discusses new therapeutic approaches for patients with metastatic triple-negative breast cancer.

Sacituzumab Govitecan Meets Primary End Point in Phase 3 ASCENT Trial

July 6th 2020

The novel antibody-drug conjugate sacituzumab govitecan-hziy demonstrated significant improvement in survival in patients with triple-negative breast cancer without brain metastases who previously received at least 2 prior therapies for metastatic disease.

Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases

July 6th 2020

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

Dr. Adams on the Utility of Combination CTLA-4 and PD-1 Blockade in Breast Cancer

July 6th 2020

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.

Next Generation of Combo Regimens Being Explored in ER+ Breast Cancer

July 2nd 2020

Hung Khong, MD, discusses the potential to combine endocrine therapy with immunotherapy in patients with ER-positive breast cancer, and other intriguing therapies poised to improve transform the pipeline.